Italia markets closed

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
0,9380-0,0042 (-0,45%)
Alla chiusura: 04:00PM EDT
0,9499 +0,01 (+1,27%)
Dopo ore: 05:51PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,9422
Aperto0,9300
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno0,9251 - 0,9422
Intervallo di 52 settimane0,8800 - 1,5700
Volume271.830
Media Volume337.304
Capitalizzazione84,073M
Beta (mensile su 5 anni)1,12
Rapporto PE (ttm)N/D
EPS (ttm)-0,9400
Prossima data utili01 ago 2024 - 05 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Chimerix to Participate in Upcoming Investor Conferences

    DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference in New York City. Mike Andriole, Chief Executive Officer, will present a corporate overview on September 12, 2023 at 9:00 a.m. ET. A l

  • GlobeNewswire

    Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

    Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the publication of data in

  • GlobeNewswire

    Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

    – Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in First Half 2024 – – Capital Available to Fund Operations is $233 Million as of June 30, 2023 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve